Buenos Aires - Delayed Quote ARS

Pfizer Inc. (PFE.BA)

Compare
8,020.00
0.00
(0.00%)
At close: January 9 at 4:53:46 PM GMT-3
Loading Chart for PFE.BA
DELL
  • Previous Close 8,020.00
  • Open 8,030.00
  • Bid 8,010.00 x --
  • Ask 8,140.00 x --
  • Day's Range 7,680.00 - 8,150.00
  • 52 Week Range 6,542.00 - 18,950.00
  • Volume 4,832
  • Avg. Volume 23,730
  • Market Cap (intraday) 157.657T
  • Beta (5Y Monthly) 0.62
  • PE Ratio (TTM) 5.16
  • EPS (TTM) 1,553.47
  • Earnings Date Feb 4, 2025
  • Forward Dividend & Yield 437.85 (5.46%)
  • Ex-Dividend Date Jan 24, 2025
  • 1y Target Est --

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

88,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PFE.BA

View More

Performance Overview: PFE.BA

Trailing total returns as of 1/9/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

PFE.BA
2.17%
S&P 500
0.19%

1-Year Return

PFE.BA
54.87%
S&P 500
24.24%

3-Year Return

PFE.BA
36.42%
S&P 500
26.54%

5-Year Return

PFE.BA
431.85%
S&P 500
81.93%

Compare To: PFE.BA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PFE.BA

View More

Valuation Measures

As of 1/9/2025
  • Market Cap

    157.66T

  • Enterprise Value

    216.35T

  • Trailing P/E

    5.16

  • Forward P/E

    1.32

  • PEG Ratio (5yr expected)

    0.03

  • Price/Sales (ttm)

    0.37

  • Price/Book (mrq)

    0.24

  • Enterprise Value/Revenue

    3.52

  • Enterprise Value/EBITDA

    15.10

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.16%

  • Return on Assets (ttm)

    3.31%

  • Return on Equity (ttm)

    4.54%

  • Revenue (ttm)

    59.38B

  • Net Income Avi to Common (ttm)

    4.27B

  • Diluted EPS (ttm)

    1,553.47

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.95B

  • Total Debt/Equity (mrq)

    73.41%

  • Levered Free Cash Flow (ttm)

    11.42B

Research Analysis: PFE.BA

View More

People Also Watch